Udit Nindra, Medical Oncologist at Liverpool Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JCO Oncology Practice:
“As early-phase clinical trials become an integral part of standard cancer care in Australia, patients are increasingly navigating the logistical and financial challenges of participation. To better understand these impacts, the Liverpool Hospital Trials Unit, in collaboration with Scientia Clinical Research, conducted the PEARLER study, assessing patient-reported financial, social, and time toxicity in early-phase cancer clinical trials.
The results are now published in JCO Oncology Practice:
Key findings:
- Objective time toxicity accounted for a median of 26% of days, though only 16% of patients perceived it as burdensome (mostly during the first two cycles).
- Financial toxicity was reported by 44%, and social role impairment by 71%, but neither worsened over six treatment cycles.
Overall, quality of life remained stable during trial participation.
These results provide reassurance that early-phase trial participation, while intensive, does not appear to worsen key patient-reported outcomes.”
Title: Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study
Authors: Udit Nindra, Joanne Tang, Jun Hee Hong, Joseph Descallar, Martin Hong, Andrew Killen, Priyadarshini Dubey, Jeneen Attaullah, Grace Scott, Adam Cooper, Kate Wilkinson, Abhijit Pal, Christina Teng, Aflah Roohullah, Joe Wei, Weng Ng, Charlotte Lemech, Wei Chua
Read the Full Article on JCO Oncology Practice
More posts about Clinical Trials.